Web
Analytics

Israeli Coronavirus Treatment Shows 100% Survival Rate In Early Trials

25

No treatment for boycott Jews (BDS) Nazis.

Quick note: Tech giants are shutting us down. You know this. Twitter, LinkedIn, Google Adsense, Pinterest permanently banned us. Facebook, Google search et al have shadow-banned, suspended and deleted us from your news feeds. They are disappearing us. But we are here. We will not waver. We will not tire. We will not falter, and we will not fail. Freedom will prevail.

Subscribe to Geller Report newsletter here — it’s free and it’s critical NOW when informed decision making and opinion is essential to America's survival. Share our posts on your social channels and with your email contacts. Fight the great fight.

Follow me on Gettr. I am there, click here. It's open and free.

Remember, YOU make the work possible. If you can, please contribute to Geller Report.

Israeli Coronavirus Treatment Shows 100% Survival Rate In Early Trials

Israeli Coronavirus Treatment Shows 100% Survival Rate In Early Trials

By J Post, April 8, 2020

Early trials of a coronavirus treatment developed by Israeli company Pluristem Therapeutics Inc.’s is showing signs of hope as the world battles with the virus.

Seven patients placed on ventilators in hospital Intensive Care Units were tested in the trial and all seven survived as a result of the treatment, according to a company press release.

“We are pleased with this initial outcome of the compassionate use program, and committed to harnessing PLX cells for the benefit of patients and healthcare systems. In order to maximize PLX cells’ impact on patient recovery and to work towards making our treatment widely available, we plan to quickly move forward into a clinical development program,” Pluristem CEO and President, Yaky Yanay said in a statement.

“Pluristem is dedicated to using its competitive advantages in large-scale manufacturing to potentially deliver PLX cells to a large number of patients in significant need. We believe that research and governmental funding may be available to Pluristem to support the use of PLX cells for patients suffering from COVID19 and are targeting such funding,”

According to the release, Pluristem is hoping to open the treatment to worldwide clinical trials.

Click here to read the full story.

Have a tip we should know? Your anonymity is NEVER compromised. Email tips@thegellerreport.com

The Truth Must be Told

Your contribution supports independent journalism

Please take a moment to consider this. Now, more than ever, people are reading Geller Report for news they won't get anywhere else. But advertising revenues have all but disappeared. Google Adsense is the online advertising monopoly and they have banned us. Social media giants like Facebook and Twitter have blocked and shadow-banned our accounts. But we won't put up a paywall. Because never has the free world needed independent journalism more.

Everyone who reads our reporting knows the Geller Report covers the news the media won't. We cannot do our ground-breaking report without your support. We must continue to report on the global jihad and the left's war on freedom. Our readers’ contributions make that possible.

Geller Report's independent, investigative journalism takes a lot of time, money and hard work to produce. But we do it because we believe our work is critical in the fight for freedom and because it is your fight, too.

Please contribute here.

or

Make a monthly commitment to support The Geller Report – choose the option that suits you best.

Pin It on Pinterest